Close Menu
    Congo StarCongo Star
    • Home
    • Contact Us
    • Automotive
    • Business
    • Entertainment
    • Health
    • Luxury
    • Lifestyle
    • News
    • Sports
    • Technology
    • Travel
    Congo StarCongo Star
    Home » Russian scientists develop fluorescent compound that halts cancer cell growth
    Health

    Russian scientists develop fluorescent compound that halts cancer cell growth

    October 1, 2025
    Facebook WhatsApp Twitter Pinterest LinkedIn Telegram Tumblr Email Reddit VKontakte

    MOSCOW, September 30, 2025: Russian scientists have developed a newly synthesized compound that combines cancer-inhibiting properties with fluorescence, a development that may improve both the detection and study of tumor cells. The compound, named 2-(3-(fluorosulfato)phenyl)benzoxazole, was created through a collaboration between Tomsk Polytechnic University, Siberian State Medical University, and the A.V. Nikolaev Institute of Inorganic Chemistry. The compound demonstrated significant cytostatic activity during laboratory testing against human cancer cell lines, specifically prostate adenocarcinoma (PC-3) and breast adenocarcinoma (MCF-7 and BT-474).

    Breakthrough compound from Russia halts growth of cancer cell lines
    Russian laboratories develop new fluorescent molecule with proven tumor-inhibiting properties.

    Cytostatic agents are characterized by their ability to stop cancer cells from dividing and proliferating, offering a mechanism to limit tumor growth without inducing immediate cell death. According to the researchers, the compound contains a benzoxazole core, a structure already known for its diverse biological properties including antimicrobial and anticancer activity. The new molecule integrates a fluorosulfate group that gives it fluorescent capabilities, allowing it to emit visible light under specific laboratory conditions. This fluorescence allows the compound to be tracked in real time during cellular interactions.

    In the study, the compound’s effects on healthy cells were also evaluated. Normal human fibroblasts showed greater resistance to the compound compared to the cancer cell lines. While the compound was generally cytostatic at lower concentrations, it displayed cytotoxic properties causing direct cell death at higher concentrations and extended exposure periods in select breast cancer lines. These findings suggest a differential biological response that could be relevant for future pharmaceutical profiling. The fluorescence properties of the compound were confirmed through photophysical analysis.

    Researchers test compound on prostate and breast cancer lines

    The compound exhibited emission in the visible spectrum, with the highest fluorescence quantum yield measured at 64 percent in an acetonitrile medium. It was also found to retain luminescent properties in solid form, indicating stability in both solution and crystalline states. Researchers employed sulfur (VI) fluoride exchange (SuFEx) chemistry to produce the compound. This synthetic method involved a two-chamber reactor and specific reagent conditions, including the use of formic acid as a solvent, to optimize the chemical yield and stability of the final product.

    The compound’s structure was validated using X-ray crystallography, which confirmed its planar aromatic system and documented intermolecular interactions responsible for its solid-state organization. While laboratory findings confirm the compound’s dual functionality, the scientists noted that the observed effects were achieved at relatively high concentrations, ranging from 50 to 200 micromolar. The compound’s impact on tumor cell lines was found to be reversible in many cases, aligning with typical characteristics of cytostatic compounds.

    Russian ministry oversees collaborative scientific development

    The research was conducted under the oversight of the Ministry of Science and Higher Education of the Russian Federation. Officials described the discovery as a notable advancement in the development of biologically active materials that serve dual roles in diagnostics and therapeutic research. Further investigations are expected to continue under controlled laboratory conditions to expand the understanding of the compound’s full biological profile, including its mechanism of action and compatibility with other research applications in cellular biology. All testing was carried out in vitro and no human or animal trials have been conducted to date. – By EuroWire News Desk.

    Related Posts

    Ebola outbreak in DRC reaches 282 confirmed cases

    June 1, 2026

    Measles outbreak in Bangladesh passes 60,000 cases

    May 23, 2026

    Ebola Bundibugyo outbreak expands health response in DRC

    May 16, 2026

    Measles outbreak in Bangladesh leaves toll at 415

    May 12, 2026

    Hantavirus probe deepens after deaths on Atlantic cruise

    May 4, 2026

    DR Congo lifts national mpox emergency after two years

    April 3, 2026
    Latest News

    Tokyo market splits as Nikkei sets closing record

    June 2, 2026

    Tokyo stocks ended mixed as the Nikkei hit a record close on tech gains while the Topix fell, showing narrow market leadership.

    China investigates fatal Huize illegal mining collapse

    June 1, 2026

    Ebola outbreak in DRC reaches 282 confirmed cases

    June 1, 2026

    Eight dead as Türkiye bus strikes highway barrier

    June 1, 2026

    AI chip demand lifts Singapore Q1 GDP growth to 6%

    May 25, 2026

    Shanxi coal mine explosion kills 82 workers

    May 25, 2026

    Measles outbreak in Bangladesh passes 60,000 cases

    May 23, 2026

    PM Modi and Meloni spotlight deepening India-Italy ties

    May 21, 2026
    © 2026 Congo Star | All Rights Reserved
    • Home
    • Contact Us

    Type above and press Enter to search. Press Esc to cancel.